Literature DB >> 32202545

Fetal alcohol spectrum disorders awareness in health professionals: implications for psychiatry.

Marisa Patrizia Messina1, Alessio D'Angelo1, Gemma Battagliese2, Giovanna Coriale2, Luigi Tarani3, Simona Pichini4, Debora Rasio5, Giovanni Parlapiano3, Marco Fiore6, Carla Petrella6, Mario Vitali7, Giampiero Ferraguti8, Mauro Ceccanti9.   

Abstract

Fetal Alcohol Spectrum Disorders (FASD) are a plethora of malformative conditions leading to mental retardation that affect newborns and children who have been exposed to alcohol during pregnancy or breastfeeding. FASD is a relevant topic for public health in Europe: European area is first in ranking for alcohol use during pregnancy with a prevalence of 25.2%. Italy ranked third among European countries with higher prevalence of FASD (45.0 per 1000 population). Furthermore, FASD could still be underestimated because of numerous undiagnosed and misdiagnosed cases. Aims of the study were to briefly summarize existing evidences about FASD and its psychiatric aspects to assess knowledge, attitudes and practice towards alcohol drinking during pregnancy in an Italian sample of health care professionals in order to provide information about FASD prevention. An anonymous online questionnaire containing the AUDIT-C, T-ACE model and the Drinking Motive Questionnaire was sent to 400 Italian healthcare professionals and students. The survey included socio-demographic information, questions about drinking habits and about knowledge, attitude and practice towards alcohol assumption during pregnancy. Among 320 respondents, 96.3% were women. AUDIT-C revealed that 52.4% were low risk drinkers but 27.6% were hazardous drinkers. The 90.6% of participants denied to ever attended a course about the fetus damage induced by alcohol consumption during pregnancy but 91.3% were willing to participate to professional update initiatives on the topic. Only 19.1% of participants talk regularly about the deleterious effects for the fetus of prenatal alcohol drinking to women and only 51.1% advise the 'zero alcohol' policy. Around 41% of participants tolerates the assumption of low-alcohol beverages. No differences were found between no drinkers and low and hazardous drinkers. In conclusion, data show that only specific and continuing updating for health care professionals about drinking habits may have impactful actions to prevent gestational alcohol intake in order to prevent the main cause of mental retardation in western countries.

Entities:  

Mesh:

Year:  2020        PMID: 32202545     DOI: 10.1708/3333.33022

Source DB:  PubMed          Journal:  Riv Psichiatr        ISSN: 0035-6484            Impact factor:   1.911


  3 in total

1.  Knowledge and Practice towards Alcohol Consumption in a Sample of University Students.

Authors:  Marisa Patrizia Messina; Alessio D'Angelo; Rosaria Ciccarelli; Fabiola Pisciotta; Luigi Tramonte; Marco Fiore; Giampiero Ferraguti; Mario Vitali; Mauro Ceccanti; Gemma Battagliese
Journal:  Int J Environ Res Public Health       Date:  2021-09-10       Impact factor: 4.614

2.  Prevalence of Fetal Alcohol Spectrum Disorders (FASD) among Children Adopted from Eastern European Countries: Russia and Ukraine.

Authors:  Joan Colom; Lidia Segura-García; Adriana Bastons-Compta; Marta Astals; Vicente Andreu-Fernandez; Natalia Barcons; Raquel Vidal; Ana I Ibar; Vicky Fumadó; Nuria Gómez; Agnés Russiñol; Oscar Garcia-Algar
Journal:  Int J Environ Res Public Health       Date:  2021-02-03       Impact factor: 3.390

Review 3.  Alcohol and Head and Neck Cancer: Updates on the Role of Oxidative Stress, Genetic, Epigenetics, Oral Microbiota, Antioxidants, and Alkylating Agents.

Authors:  Giampiero Ferraguti; Sergio Terracina; Carla Petrella; Antonio Greco; Antonio Minni; Marco Lucarelli; Enzo Agostinelli; Massimo Ralli; Marco de Vincentiis; Giammarco Raponi; Antonella Polimeni; Mauro Ceccanti; Brunella Caronti; Maria Grazia Di Certo; Christian Barbato; Alessandro Mattia; Luigi Tarani; Marco Fiore
Journal:  Antioxidants (Basel)       Date:  2022-01-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.